Table 1.
Demographics and clinical details (n = 227)
| Type I iEOC (n = 60) | Type II iEOC (n = 134) | Borderline ovarian tumours (n = 33) | |
|---|---|---|---|
| Age at diagnosis, (years) | |||
| Mean (±SD) | 62.2 (10.7) | 65.3 (9.8) | 63.9 (12.2) |
| Range | 46–83 | 46–90 | 45–87 |
| Ethnicity | |||
| White | 57 (95%) | 130 (97%) | 33 (100%) |
| Other | 3 (5%) | 4 (3%) | 0 (0%) |
| Menopausal status | |||
| Unknown | 5 (8%) | 1 (1%) | – |
| Perimenopausal | 10 (17%) | 14 (10%) | 3 (9%) |
| Postmenopausal | 45 (75%) | 119 (89%) | 30 (91%) |
| Using HRT | 9 (20%) | 43 (36%) | 8 (27%) |
| Not using HRT | 28 (62%) | 65 (55%) | 21 (70%) |
| Unknown if using HRT | 8 (18%) | 11 (9%) | 1 (3%) |
| FIGO stage | |||
| I | 42 (70%) | 14 (10%) | 24 (73%) |
| II | 5 (8%) | 14 (10%) | 0 (0%) |
| III | 11 (18%) | 80 (60%) | 3 (9%) |
| IV | 2 (3%) | 25 (19%) | 0 (0%) |
| Unstaged | – | 1 (1%) | 6 (18%) |
| Tumour grade | |||
| 1 | 23 (38%) | – | NA |
| 2 | 18 (30%) | 22 (16%) | |
| 3 | 12 (20%) | 91 (68%) | |
| Unknown | 7 (12%) | 21 (16%) | |
HRT, hormone replacement therapy.